NFXF Blog
Featured
These strategies are based on the fundamental principles of time-out, while incorporating adaptations that address the fact that children with Fragile X syndrome have language and attention difficulties that are best accommodated through additional considerations for repetition, consistency, and predictability.
‘Fishing for a Cureʼ Reels in Over $20,000 This Year!
12 mins read
FORE! Fragile X Annual Golf Event Raises over $63,000 (So Far!)
05 mins read
RECONNECT Q&A
Mirum Launches Phase 2 Trial of MRM-3379 for Fragile X Syndrome
03 mins read
All Articles
Research Summary: The results found from the EEGs in both the FMR1 KO mice and humans with FXS are extremely important for the future of FXS research because they show a measurable commonality between the two very different species.
Allos Pharma announced they held a meeting with the FDA to optimize the design of their Phase 3 trial designed to support an NDA to address FXS.
RECONNECT is designed to confirm results of the first randomized, double-blind, placebo-controlled trial of ZYN002 conducted in FXS, CONNECT-FX.
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
